Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Semaglutide (Ozempic) is 1 of 15 medications that will be included in yearly price negotiations between Medicare and ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Factors with the greatest impact on estimated cost-effectiveness were medication impact on mortality and medication cost. When the price of semaglutide was reduced by 50%, it was economically ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...